Herrera Victoria L M, Bagamasbad Pia, Didishvili Tamara, Decano Julius L, Ruiz-Opazo Nelson
Section of Molecular Medicine, Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA 02118, USA.
Physiol Genomics. 2008 Jun 12;34(1):65-77. doi: 10.1152/physiolgenomics.00199.2007. Epub 2008 Apr 15.
The angiotensin-vasopressin receptor (AVR) responds with equivalent affinities to angiotensin II (ANG II) and vasopressin and is coupled to adenylate cyclase and hence a V2-type vasopressin receptor. AVR maps to the Nalp6 locus and overlaps with the larger Nalp6/PYPAF5 reported to be a T cell/granulocyte-specific, cytoplasmic-specific proapoptotic protein, thus questioning the existence of AVR. Here we confirm, through different experimental modalities, that AVR is distinct from Nalp6/PYPAF5 based on different mRNA and protein sizes, subcellular localization, and tissue-specific expression patterns. Binding studies of PYPAF5-specific Cos1 transfectants detect high-affinity binding to vasopressin but not ANG II, thus assigning PYPAF5 as a non-AVR (NAVR). Signaling array analysis reveals that AVP stimulation of AVR- and NAVR-specific Cos1 transfectants results in diametrical activation as well as coactivation of signaling pathways known to mediate renal sodium and water balance. Likewise, ANG II stimulation of Cos1-AVR transfectants reveals a signaling profile distinct from that of AVP-stimulated Cos1-AVR transfectants. Analysis of genomic organization of the AVR/NAVR locus shows an overlapping gene arrangement with alternative promoter usage resulting in different NH(2) termini for NAVR and AVR. In addition to core promoter elements, androgen and estrogen response elements are detected. Promoter analysis of NAVR/AVR 5'-regulatory region detects transcriptional upregulation by testosterone and synergistic upregulation by testosterone and estrogen, thus suggesting that AVR and/or NAVR contribute to sex-specific V2-type vasopressin-mediated effects. Altogether, confirmation of AVR and identification of NAVR as vasopressin receptors are concordant with emerging vasopressin functions not attributable to V1a, V1b, or V2 receptors and add molecular bases for the multifunctional complexity of vasopressin-mediated functions and regulation.
血管紧张素 - 加压素受体(AVR)对血管紧张素II(ANG II)和加压素具有同等亲和力,并与腺苷酸环化酶偶联,因此是一种V2型加压素受体。AVR定位于Nalp6基因座,与报道的更大的Nalp6 / PYPAF5重叠,后者是一种T细胞/粒细胞特异性、细胞质特异性促凋亡蛋白,因此对AVR的存在提出了质疑。在这里,我们通过不同的实验方式证实,基于不同的mRNA和蛋白质大小、亚细胞定位以及组织特异性表达模式,AVR与Nalp6 / PYPAF5不同。对PYPAF5特异性Cos1转染子的结合研究检测到与加压素的高亲和力结合,但未检测到与ANG II的结合,因此将PYPAF5指定为非AVR(NAVR)。信号阵列分析表明,AVP对AVR和NAVR特异性Cos1转染子的刺激导致信号通路的完全激活以及已知介导肾钠和水平衡的信号通路的共同激活。同样,ANG II对Cos1 - AVR转染子的刺激揭示了与AVP刺激的Cos1 - AVR转染子不同的信号谱。对AVR / NAVR基因座的基因组组织分析显示,存在重叠基因排列以及不同的启动子使用情况,导致NAVR和AVR具有不同的NH(2)末端。除了核心启动子元件外,还检测到雄激素和雌激素反应元件。对NAVR / AVR 5' - 调控区的启动子分析检测到睾酮的转录上调以及睾酮和雌激素的协同上调,因此表明AVR和/或NAVR有助于性别特异性V2型加压素介导的效应。总之,AVR的证实以及NAVR作为加压素受体的鉴定与新兴的加压素功能一致,这些功能不归因于V1a、V1b或V2受体,并为加压素介导的功能和调节的多功能复杂性增加了分子基础。